Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation
Recruiting
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Other: Secukinumab
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT06517732
- Locations
- 🇷🇺
Novartis Investigative Site, Tula, Russian Federation
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Recruiting
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Other: lutetium (177Lu) vipivotide tetraxetan
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT06517719
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Post Marketing Study on Pluvicto in Korea
Not yet recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Other: Lutetium vipivotide tetraxetan
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 278
- Registration Number
- NCT06514521
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Phase 2
Recruiting
- Conditions
- Chronic Myeloid Leukemia (CML)
- Interventions
- Drug: ABL001/Asciminib
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT06514534
- Locations
- 🇫🇷
Novartis Investigative Site, Lyon, France
LATAM LOWERS LDL-C
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 520
- Registration Number
- NCT06501443
- Locations
- 🇧🇷
Novartis Investigative Site, Salvador, Brazil
Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study
Recruiting
- Conditions
- Relapsing Multiple Sclerosis (RMS)
- Interventions
- Other: Ofatumumab
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT06486779
- Locations
- 🇬🇷
Novartis Investigative Site, Larissa, Thessalia, Greece
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Phase 2
Recruiting
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06470048
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
🇺🇸Sarasota Arthritis Res Ctr, Sarasota, Florida, United States
🇺🇸Prolato Clinical Research Center, Houston, Texas, United States
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
Phase 4
Recruiting
- Conditions
- Steroid-refractory Acute Graft Versus Host Disease
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT06462469
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT06460324
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation
Recruiting
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Other: secukinumab
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 177
- Registration Number
- NCT06444087
- Locations
- 🇫🇷
Novartis Investigative Site, Vannes, France
© Copyright 2025. All Rights Reserved by MedPath